HOME HELP SUBSCRIBE ARCHIVE SEARCH TABLE OF CONTENTS FEEDBACK EDITORIAL BOARD ABOUT DOC NEWS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                What's this?

TALK BACK: GAUGING THE ROSIGLITAZONE RESPONSE

Some in the diabetes community contend that the rosiglitazone heart risk is overblown, and that GlaxoSmithKline hasn't had a chance to adequately defend itself against the political furor surrounding the drug—an uproar that may threaten its future distribution.

What do you think? Has the media and political response to the rosiglitazone meta-analysis been appropriate?

Send your comments to docnews{at}diabetes.org.

References

1. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med [Epub ahead of print May 21] 2007. Available online at http://content.nejm.org/cgi/content/abstract/NEJMoa072761v1. Accessed June 26, 2007.

CiteULike

Del.icio.us

Digg

Reddit

Technorati

Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                What's this?